Kalvista pharmaceuticals presents data at eastern allergy conference 2024 and the japanese dermatological association 2024

Cambridge, mass. & salisbury, england--(business wire)--kalvista pharmaceuticals, inc. (nasdaq: kalv), today announced that it presented the us subgroup analysis from the sebetralstat phase 3 konfident trial and real-world claims and patient survey data at the eastern allergy conference (eac) 2024, as well as the japanese subgroup from konfident at the 123rd annual meeting of the japanese dermatological association (jda) 2024. konfident is the first pivotal phase 3 trial to include japanese sit.
EML Ratings Summary
EML Quant Ranking